ArticleLeukemia2022

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.

Jooeun Bae et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.